100 related articles for article (PubMed ID: 32527614)
1. VPS41-BRAF, a novel BRAF fusion gene identified in a lung adenocarcinoma patient by next-generation sequencing.
Wang L; Chen A; She X; Xiang J; Tang J
Lung Cancer; 2020 Aug; 146():380-381. PubMed ID: 32527614
[No Abstract] [Full Text] [Related]
2. A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib.
Zhu YC; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
Clin Lung Cancer; 2019 May; 20(3):e224-e228. PubMed ID: 30914311
[No Abstract] [Full Text] [Related]
3. Pulmonary Enteric Adenocarcinoma Harboring a BRAF G469V Mutation.
Shimizu D; Yamamoto H; Shien K; Taniguchi K; Miyoshi K; Namba K; Mesaki K; Sugimoto S; Soh J; Yamane M; Toyooka S
Acta Med Okayama; 2021 Dec; 75(6):759-762. PubMed ID: 34955547
[TBL] [Abstract][Full Text] [Related]
4. PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
Wang B; Chen R; Wang C; Chen H; Zhong D
Lung Cancer; 2021 Mar; 153():176-178. PubMed ID: 33483162
[No Abstract] [Full Text] [Related]
5. A novel 5'ALK fusion identified by next generation sequencing and validated by IHC in a patient with lung adenocarcinoma.
He Z; Zhu X; Zeng Q; Yu Z
Lung Cancer; 2021 Aug; 158():164-165. PubMed ID: 34120772
[No Abstract] [Full Text] [Related]
6. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
[No Abstract] [Full Text] [Related]
7. Does V600E BRAF mutation predict vinorelbine efficacy? A proof-of-concept from a lung micropapillary adenocarcinoma metastatic to the breast.
Carassai P; Jocollé G; Donati G; Spinazzé S; Baiocco C; Baderna P; Martinet A; Lococo F; Migliaccio F; Rossi G
Pathologica; 2017 Dec; 109(4):426-428. PubMed ID: 29449740
[No Abstract] [Full Text] [Related]
8. A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation.
Olofson AM; Tafe LJ
Exp Mol Pathol; 2018 Feb; 104(1):26-28. PubMed ID: 29248665
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
Zhu YC; Wang WX; Xu CW; Zhang QX; Du KQ; Chen G; Lv TF; Song Y
Ann Oncol; 2018 Dec; 29(12):2392-2393. PubMed ID: 30339198
[No Abstract] [Full Text] [Related]
10. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
[No Abstract] [Full Text] [Related]
11. Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma.
Chang LC; Chen KY; Shih JY; Yu CJ; Hsieh MS
J Thorac Oncol; 2017 Jul; 12(7):e94-e95. PubMed ID: 28629547
[No Abstract] [Full Text] [Related]
12. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
Leblond AL; Rechsteiner M; Jones A; Brajkovic S; Dupouy D; Soltermann A
Am J Clin Pathol; 2019 Jun; 152(1):59-73. PubMed ID: 31065676
[TBL] [Abstract][Full Text] [Related]
13. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
Jang JS; Lee A; Li J; Liyanage H; Yang Y; Guo L; Asmann YW; Li PW; Erickson-Johnson M; Sakai Y; Sun Z; Jeon HS; Hwang H; Bungum AO; Edell ES; Simon VA; Kopp KJ; Eckloff B; Oliveira AM; Wieben E; Aubry MC; Yi E; Wigle D; Diasio RB; Yang P; Jen J
Sci Rep; 2015 May; 5():9755. PubMed ID: 25985019
[TBL] [Abstract][Full Text] [Related]
14. SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing.
Hou X; Xu H; Chen L
J Thorac Oncol; 2019 Apr; 14(4):e72-e73. PubMed ID: 30922581
[No Abstract] [Full Text] [Related]
15. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
[TBL] [Abstract][Full Text] [Related]
16. A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
Boyle TA; Quinn GP; Schabath MB; Muñoz-Antonia T; Saller JJ; Duarte LF; Hair LS; Teer JK; Chiang DY; Leary R; Wong CC; Savchenko A; Singh AP; Charette L; Mendell K; Gorgun G; Antonia SJ; Chiappori AA; Creelan BC; Gray JE; Haura EB
Cancer Med; 2020 Jan; 9(1):225-237. PubMed ID: 31747139
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
18. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.
Abravanel DL; Nishino M; Sholl LM; Ambrogio C; Awad MM
J Thorac Oncol; 2018 Aug; 13(8):e131-e133. PubMed ID: 29631033
[No Abstract] [Full Text] [Related]
19. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
20. Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.
Tsakonas G; Grozman V; Ekman S
Clin Lung Cancer; 2020 Nov; 21(6):e544-e546. PubMed ID: 32522509
[No Abstract] [Full Text] [Related]
[Next] [New Search]
